Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

182.69
-6.4600-3.42%
Post-market: 182.690.00000.00%19:36 EDT
Volume:827.04K
Turnover:152.69M
Market Cap:11.25B
PE:-31.28
High:189.26
Open:189.26
Low:182.55
Close:189.15
52wk High:198.00
52wk Low:95.49
Shares:61.56M
Float Shares:58.65M
Volume Ratio:0.83
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8403
EPS(LYR):-5.8403
ROE:-8.47%
ROA:5.38%
PB:2.60
PE(LYR):-31.28

Loading ...

Jazz Pharmaceuticals Plc : Barclays Initiates Coverage With Overweight Rating; Target Price $224

THOMSON REUTERS
·
Feb 27

Saniona FY 2025 revenue rises 29.8% to SEK 434.4 million

Reuters
·
Feb 26

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies

TIPRANKS
·
Feb 25

Stock Track | Jazz Pharmaceuticals Soars 6.99% Intraday on Multiple Analyst Price Target Hikes

Stock Track
·
Feb 25

Morgan Stanley Lifts Price Target on Jazz Pharmaceuticals to $226 From $225, Keeps Overweight Rating

MT Newswires Live
·
Feb 25

Jazz Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Feb 25

Jazz Pharmaceuticals Plc : Deutsche Bank Raises Target Price to $255 From $210

THOMSON REUTERS
·
Feb 25

Stock Track | Jazz Pharmaceuticals Soars 5.28% in Pre-Market on Multiple Analyst Price Target Hikes

Stock Track
·
Feb 25

Jazz Pharmaceuticals price target raised to $250 from $235 at Wells Fargo

TIPRANKS
·
Feb 25

Jazz Pharmaceuticals Plc : Wells Fargo Raises Target Price to $250 From $235

THOMSON REUTERS
·
Feb 25

Earnings Flash (JAZZ) Jazz Pharmaceuticals Posts Q4 Revenue $1.2B, vs. FactSet Est of $1.17B

MT Newswires Live
·
Feb 25

Ireland's Jazz Pharmaceuticals beats Q4 revenue, profit estimates

Reuters
·
Feb 25

Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.5B

TIPRANKS
·
Feb 25

BRIEF-Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.64 Vs. IBES Estimate USD 6.52

Reuters
·
Feb 25

Jazz Pharmaceuticals Q4 EPS USD 3.21

THOMSON REUTERS
·
Feb 25

Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.64 VS. Ibes Estimate USD 6.52

THOMSON REUTERS
·
Feb 25

Jazz Pharmaceuticals Outlook FY Revenue USD 4,250-4,500 Million

THOMSON REUTERS
·
Feb 25

BRIEF-UK's MHRA Approves Zanidatamab For Treatment Of Biliary Tract Cancer

Reuters
·
Feb 19

Jazz Pharmaceuticals Gets UK Approval for Biliary Tract Cancer Treatment

MT Newswires Live
·
Feb 19

UK's Mhra: Approves Zanidatamab (Ziihera) for the Treatment of Biliary Tract Cancer

THOMSON REUTERS
·
Feb 19